Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999075488> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W1999075488 endingPage "32" @default.
- W1999075488 startingPage "26" @default.
- W1999075488 abstract "With the advent of biological therapies for the treatment of plaque psoriasis, guidance on the usage of these new agents has become necessary. One such agent, efalizumab, a humanized recombinant monoclonal IgG1 antibody developed to target T-cell-mediated inflammation, provides rapid and sustained efficacy for many psoriasis patients. This article explores the pretreatment, initiation, and treatment phases with efalizumab therapy. In the pretreatment phase, physicians need to assess patients’ disease state and educate them about the course of efalizumab treatment. Prior to initiation, physicians need to establish stable disease, ensure an adequate transition or washout of any prior psoriasis therapeutics, and obtain baseline platelet counts. After initiating treatment, both physician and patient must participate in disease monitoring. Patients responding favourably may receive continuous treatment. Those who do not respond to the drug or who experience adverse events should be managed appropriately in order to continue therapy or be transitioned onto another agent. A growing body of clinical evidence, as well as experience from clinical investigators, has provided much insight into the management strategies for patients undergoing treatment with efalizumab." @default.
- W1999075488 created "2016-06-24" @default.
- W1999075488 creator A5000743912 @default.
- W1999075488 creator A5008286260 @default.
- W1999075488 creator A5018770087 @default.
- W1999075488 creator A5021906179 @default.
- W1999075488 creator A5037699740 @default.
- W1999075488 creator A5061849637 @default.
- W1999075488 creator A5069977428 @default.
- W1999075488 creator A5076177681 @default.
- W1999075488 date "2005-12-01" @default.
- W1999075488 modified "2023-09-25" @default.
- W1999075488 title "Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis" @default.
- W1999075488 cites W2007113430 @default.
- W1999075488 cites W2012009723 @default.
- W1999075488 cites W2019217317 @default.
- W1999075488 cites W2033040352 @default.
- W1999075488 cites W2044221229 @default.
- W1999075488 cites W2050754524 @default.
- W1999075488 cites W2076246528 @default.
- W1999075488 cites W2141008039 @default.
- W1999075488 cites W2141267524 @default.
- W1999075488 cites W2154955762 @default.
- W1999075488 cites W2159011171 @default.
- W1999075488 cites W2878403573 @default.
- W1999075488 cites W4233697697 @default.
- W1999075488 cites W4241502642 @default.
- W1999075488 cites W4249483860 @default.
- W1999075488 doi "https://doi.org/10.1007/s10227-006-0104-0" @default.
- W1999075488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16633859" @default.
- W1999075488 hasPublicationYear "2005" @default.
- W1999075488 type Work @default.
- W1999075488 sameAs 1999075488 @default.
- W1999075488 citedByCount "8" @default.
- W1999075488 crossrefType "journal-article" @default.
- W1999075488 hasAuthorship W1999075488A5000743912 @default.
- W1999075488 hasAuthorship W1999075488A5008286260 @default.
- W1999075488 hasAuthorship W1999075488A5018770087 @default.
- W1999075488 hasAuthorship W1999075488A5021906179 @default.
- W1999075488 hasAuthorship W1999075488A5037699740 @default.
- W1999075488 hasAuthorship W1999075488A5061849637 @default.
- W1999075488 hasAuthorship W1999075488A5069977428 @default.
- W1999075488 hasAuthorship W1999075488A5076177681 @default.
- W1999075488 hasConcept C126322002 @default.
- W1999075488 hasConcept C16005928 @default.
- W1999075488 hasConcept C177713679 @default.
- W1999075488 hasConcept C197934379 @default.
- W1999075488 hasConcept C2779134260 @default.
- W1999075488 hasConcept C2780035454 @default.
- W1999075488 hasConcept C2780564577 @default.
- W1999075488 hasConcept C2780969348 @default.
- W1999075488 hasConcept C3020604521 @default.
- W1999075488 hasConcept C535046627 @default.
- W1999075488 hasConcept C71924100 @default.
- W1999075488 hasConcept C98274493 @default.
- W1999075488 hasConceptScore W1999075488C126322002 @default.
- W1999075488 hasConceptScore W1999075488C16005928 @default.
- W1999075488 hasConceptScore W1999075488C177713679 @default.
- W1999075488 hasConceptScore W1999075488C197934379 @default.
- W1999075488 hasConceptScore W1999075488C2779134260 @default.
- W1999075488 hasConceptScore W1999075488C2780035454 @default.
- W1999075488 hasConceptScore W1999075488C2780564577 @default.
- W1999075488 hasConceptScore W1999075488C2780969348 @default.
- W1999075488 hasConceptScore W1999075488C3020604521 @default.
- W1999075488 hasConceptScore W1999075488C535046627 @default.
- W1999075488 hasConceptScore W1999075488C71924100 @default.
- W1999075488 hasConceptScore W1999075488C98274493 @default.
- W1999075488 hasIssue "S1" @default.
- W1999075488 hasLocation W19990754881 @default.
- W1999075488 hasLocation W19990754882 @default.
- W1999075488 hasOpenAccess W1999075488 @default.
- W1999075488 hasPrimaryLocation W19990754881 @default.
- W1999075488 hasRelatedWork W1987383335 @default.
- W1999075488 hasRelatedWork W1989566109 @default.
- W1999075488 hasRelatedWork W2007336508 @default.
- W1999075488 hasRelatedWork W204496304 @default.
- W1999075488 hasRelatedWork W2130000013 @default.
- W1999075488 hasRelatedWork W2203800761 @default.
- W1999075488 hasRelatedWork W2398457950 @default.
- W1999075488 hasRelatedWork W2404038155 @default.
- W1999075488 hasRelatedWork W2578647328 @default.
- W1999075488 hasRelatedWork W4234345907 @default.
- W1999075488 hasVolume "9" @default.
- W1999075488 isParatext "false" @default.
- W1999075488 isRetracted "false" @default.
- W1999075488 magId "1999075488" @default.
- W1999075488 workType "article" @default.